Cargando…
Targeting Base Excision Repair in Cancer: NQO1-Bioactivatable Drugs Improve Tumor Selectivity and Reduce Treatment Toxicity Through Radiosensitization of Human Cancer
Ionizing radiation (IR) creates lethal DNA damage that can effectively kill tumor cells. However, the high dose required for a therapeutic outcome also damages healthy tissue. Thus, a therapeutic strategy with predictive biomarkers to enhance the beneficial effects of IR allowing a dose reduction wi...
Autores principales: | Starcher, Colton L., Pay, S. Louise, Singh, Naveen, Yeh, I-Ju, Bhandare, Snehal B., Su, Xiaolin, Huang, Xiumei, Bey, Erik A., Motea, Edward A., Boothman, David A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468503/ https://www.ncbi.nlm.nih.gov/pubmed/32974194 http://dx.doi.org/10.3389/fonc.2020.01575 |
Ejemplares similares
-
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone
por: Chakrabarti, Gaurab, et al.
Publicado: (2015) -
Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy
por: Singh, Naveen, et al.
Publicado: (2020) -
Membrane‐Permeant, Bioactivatable Coumarin Derivatives for In‐Cell Labelling
por: Schultz, Madeleine, et al.
Publicado: (2022) -
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance
por: Li, Xiaoguang, et al.
Publicado: (2019) -
NQO1 protects against clioquinol toxicity
por: Chhetri, Jamuna, et al.
Publicado: (2022)